<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00847912</url>
  </required_header>
  <id_info>
    <org_study_id>562</org_study_id>
    <nct_id>NCT00847912</nct_id>
  </id_info>
  <brief_title>CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial</brief_title>
  <acronym>VAKCCT</acronym>
  <official_title>CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to see if 5-fluorouracil (5-FU) skin cream can prevent the
      growth of new skin cancers on the face and ears. The cost of trying to prevent skin cancer
      will be compared to the usual cost of treating skin cancer. Participants are being asked to
      be a part of this study because the participants have been treated for two or more skin
      cancers within the past five (5) years. At least one of these cancers occurred on the face or
      ears. Having had two or more skins cancers in the past 5 years makes it likely that
      participants will develop additional skin cancers in the future.

      Exposure to ultraviolet radiation from the sun or artificial sources such as tanning beds is
      a major cause of basal cell and squamous cell carcinoma of the skin. Using lotions, creams,
      or gels that contain sunscreens can help protect the skin from premature aging and damage
      that may lead to skin cancer.

      The 5-FU skin cream used in this study is FDA-approved to treat some types of skin cancers
      and spots that might become skin cancer. However, 5-FU skin cream has never been studied to
      see if it can prevent skin cancer. This drug is not approved by the FDA for how it will be
      used in this study.

      In this study, one half of the patients will use the 5-FU cream and the other half will use a
      skin cream that looks identical to the 5-FU cream but does not have 5-FU or any other active
      drug in it.

      Approximately twelve VA medical centers will work together in this study. About one thousand
      (1000) patients will be in this study. The study is sponsored by the U.S. Department of
      Veterans Affairs Cooperative Studies Program.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the skin, both of which are
      keratinocyte carcinomas (KCs), account for a half of all cancers in the United States, and
      over 100,000 diagnoses per year in the VA. The standard treatment for these KCs is excision
      of the lesion, and they cost the US health care system some $2.5 billion annually and about
      $100 million annually in the VA. There is no proven means to prevent KCs (except perhaps for
      a modest benefit of intensive daily sunscreen use). An effective prevention strategy would
      dramatically change the way high-risk patients are managed and could substantially reduce the
      costs of care. The investigators' preliminary analysis indicates that the savings will be
      $116 per high-risk patient and will account for a total national savings of over $11 million.
      These findings imply that the study would pay for itself by the end of 4 years. The
      investigators hypothesize that topical 5-fluorouracil (5-FU) chemoprevention will prevent
      skin cancer surgeries and will be cost-saving. To test this the investigators propose a
      randomized controlled trial of 5-FU compared to a vehicle control to the face and ears in a
      high-risk population.

      In the study, 1000 Veterans at high-risk of skin cancer defined as at least 2 KCs in the
      prior 5 years, at least one of which was on the face or ears, will be randomized to 5-FU or a
      vehicle control cream, and followed for 2 to 4 years. The primary endpoint will be surgery
      for any KC on the face and ears. The investigators will also assess the cost of care, quality
      of life, the side effects associated with treatment, and the prevalence and number of actinic
      keratoses, a skin cancer precursor and itself a cause of morbidity and cost. By targeting
      patients at high-risk, the study focuses on high-cost patients for whom this treatment could
      both improve outcomes (cancers and quality of life) and reduce costs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 26, 2009</start_date>
  <completion_date type="Actual">July 30, 2016</completion_date>
  <primary_completion_date type="Actual">June 28, 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Time to Diagnosis of the First Keratinocyte Carcinoma (KC) on the Face or Ears for Which Surgery is Performed</measure>
    <time_frame>From randomization to last visit prior to end of study date (6/30/2013), assessed up to four years</time_frame>
    <description>Diagnosis of the first Primary Basil Cell Carcinoma (BCC) or primary Squamous Cell Carcinoma (SCC) on the face or ears that was removed surgically.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hazard Ratio for Surgically Treated KC</measure>
    <time_frame>date of randomization to last visit before end of study follow up (6/30/2013), assessed up to four years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">954</enrollment>
  <condition>Carcinoma, Basal Cell</condition>
  <condition>Carcinoma, Squamous Cell</condition>
  <condition>Skin Neoplasms</condition>
  <condition>Skin Diseases</condition>
  <condition>Neoplasms, Basal Cell</condition>
  <condition>Neoplasms, Squamous Cell</condition>
  <condition>Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm 1: 5-fluorouracil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group assigned to blinded 5-FU (5-fluorouracil) cream applied to face and ears twice daily for maximum of 56 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group assigned to blinded placebo, vehicle control cream applied to face and ears twice daily for maximum of 56 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>Apply thin layer of topical 5-FU 5% cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily 5-FU, they will discontinue the treatment and initiate &quot;cool-down&quot; treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping 5-FU, if and only if the participant has not received at least the minimum 2 week (28 dose) course, 5-FU treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the &quot;cool-down&quot; routine will be followed, but 5-FU will be stopped.</description>
    <arm_group_label>Arm 1: 5-fluorouracil</arm_group_label>
    <other_name>Efudex, 5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, vehicle control</intervention_name>
    <description>Apply thin layer of vehicle control cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily vehicle control cream, they will discontinue the treatment and initiate &quot;cool-down&quot; treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping vehicle control cream, if and only if the participant has not received at least the minimum 2 week (28 dose) course, vehicle control cream treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the &quot;cool-down&quot; routine will be followed, but vehicle control cream will be stopped.</description>
    <arm_group_label>Arm 2: Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Veteran who is at high risk for developing skin cancer defined as 2 keratinocyte
             carcinomas in the past 5 years, at least one of which was located on the face or ears

        Exclusion Criteria:

          -  Participants who are unable to speak English

          -  Participants with KC at randomization

          -  Participants currently using or having used field therapy for AKs on the face or ears
             in the past 3 years. The vast majority of these field treatments would have been with
             5-FU cream. The investigators will allow recent use of therapies that are applied to
             individual AK lesions (e.g. cryotherapy), but not those that were used on an entire
             area (field) in the study treatment area Participants currently using or having used
             systemic 5-fluorouracil or oral capecitabine (Xeloda) within the past 3 years
             Participants with known allergy to sunscreen, triamcinolone and/or 5-fluorouracil.

        Exclusions 6-l0: The investigators will exclude the small proportion who get their KCs for
        special reasons other than ultraviolet radiation exposure (see list below), since that
        etiologic difference, which is associated with a prognostic difference, could be associated
        with a biologic difference in response to chemoprevention efforts. These will include:

          -  Solid organ transplant recipients, such as renal, hepatic, or cardiac transplant
             patients

          -  Individuals with genetic disorders associated with very high cancer risk such as:

          -  basal cell nevus syndrome

          -  erythrodysplasia verruciformis

          -  xeroderma pigmentosum

          -  Arsenic exposure

          -  PUVA (Psoralen plus UVA) treatment

          -  Cutaneous T-cell lymphoma

          -  Prior or current radiation therapy to the face and/or ears.

        Additional exclusions (12-15) are:

          -  Those who, in the opinion of the recruiting investigator, have very high mortality
             risk at randomization (less than 50% chance of surviving 4 years) due to co morbid
             illness such as metastatic cancer or COPD.

          -  For women of childbearing potential an initial pregnancy test and ongoing birth
             control will be required for participation.

          -  Patients with known dihydropyrimidine dehydrogenase (DPD) enzyme deficiency by self
             report or noted in the medical record (they have increased toxicity from systemic
             5-FU, although screening for this is not part of dermatologic practice and will not be
             part of this study).

          -  Patients on methotrexate (these will constitute about 1% of potentially eligible
             individuals) because they may have more severe reactions to topical 5-FU.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin A. Weinstock, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Providence VA Medical Center, Providence, RI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Palo Alto Health Care System, Palo Alto, CA</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304-1290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA San Diego Healthcare System, San Diego, CA</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Eastern Colorado Health Care System, Denver, CO</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Pines VA Healthcare System, Pay Pines, FL</name>
      <address>
        <city>Bay Pines</city>
        <state>Florida</state>
        <zip>33744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami VA Healthcare System, Miami, FL</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta VA Medical and Rehab Center, Decatur, GA</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward Hines Jr. VA Hospital, Hines, IL</name>
      <address>
        <city>Hines</city>
        <state>Illinois</state>
        <zip>60141-5000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis VA Health Care System, Minneapolis, MN</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durham VA Medical Center, Durham, NC</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia VA Medical Center, Philadelphia, PA</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence VA Medical Center, Providence, RI</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Valley Healthcare System Nashville Campus, Nashville, TN</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212-2637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lee KC, Lew R, Weinstock MA. Improvement in precision of counting actinic keratoses. Br J Dermatol. 2014 Jan;170(1):188-91. doi: 10.1111/bjd.12629.</citation>
    <PMID>24102420</PMID>
  </reference>
  <reference>
    <citation>Korgavkar K, Firoz EF, Xiong M, Lew R, Marcolivio K, Burnside N, Dyer R, Weinstock MA; VAKCC Trial Group. Measuring the severity of topical 5-fluorouracil toxicity. J Cutan Med Surg. 2014 Jul-Aug;18(4):229-35.</citation>
    <PMID>25008439</PMID>
  </reference>
  <reference>
    <citation>Pomerantz H, Hogan D, Eilers D, Swetter SM, Chen SC, Jacob SE, Warshaw EM, Stricklin G, Dellavalle RP, Sidhu-Malik N, Konnikov N, Werth VP, Keri J, Lew R, Weinstock MA; Veterans Affairs Keratinocyte Carcinoma Chemoprevention (VAKCC) Trial Group. Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial. JAMA Dermatol. 2015 Sep;151(9):952-60. doi: 10.1001/jamadermatol.2015.0502.</citation>
    <PMID>25950503</PMID>
  </reference>
  <reference>
    <citation>Chen SC, Hill ND, Veledar E, Swetter SM, Weinstock MA. Reliability of quantification measures of actinic keratosis. Br J Dermatol. 2013 Dec;169(6):1219-22. doi: 10.1111/bjd.12591.</citation>
    <PMID>24033340</PMID>
  </reference>
  <results_reference>
    <citation>Siegel JA, Chren MM, Weinstock MA; Department of Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial Group. Correlates of skin-related quality of life (QoL) in those with multiple keratinocyte carcinomas (KCs): A cross-sectional study. J Am Acad Dermatol. 2016 Sep;75(3):639-642. doi: 10.1016/j.jaad.2016.05.008.</citation>
    <PMID>27543222</PMID>
  </results_reference>
  <results_reference>
    <citation>Yoon J, Phibbs CS, Chow A, Pomerantz H, Weinstock MA. Costs of Keratinocyte Carcinoma (Nonmelanoma Skin Cancer) and Actinic Keratosis Treatment in the Veterans Health Administration. Dermatol Surg. 2016 Sep;42(9):1041-7. doi: 10.1097/DSS.0000000000000820.</citation>
    <PMID>27465252</PMID>
  </results_reference>
  <results_reference>
    <citation>Pomerantz H, Korgavkar K, Lee KC, Lew R, Weinstock MA; VAKCC Trial Group. Validation of Photograph-Based Toxicity Score for Topical 5-Fluorouracil Cream Application. J Cutan Med Surg. 2016 Sep;20(5):458-66. doi: 10.1177/1203475416643952. Epub 2016 Apr 18.</citation>
    <PMID>27207349</PMID>
  </results_reference>
  <results_reference>
    <citation>Siegel JA, Luber AJ, Weinstock MA; Department of Veterans Affairs Topical Tretinoin Chemoprevention Trial and Department of Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial Groups. Predictors of actinic keratosis count in patients with multiple keratinocyte carcinomas: A cross-sectional study. J Am Acad Dermatol. 2017 Feb;76(2):346-349. doi: 10.1016/j.jaad.2016.09.020.</citation>
    <PMID>28088997</PMID>
  </results_reference>
  <results_reference>
    <citation>Walker JL, Siegel JA, Sachar M, Pomerantz H, Chen SC, Swetter SM, Dellavalle RP, Stricklin GP, Qureshi AA, DiGiovanna JJ, Weinstock MA. 5-Fluorouracil for Actinic Keratosis Treatment and Chemoprevention: A Randomized Controlled Trial. J Invest Dermatol. 2017 Jun;137(6):1367-1370. doi: 10.1016/j.jid.2016.12.029.</citation>
    <PMID>28532759</PMID>
  </results_reference>
  <results_reference>
    <citation>Pomerantz H, Chren MM, Lew R, Weinstock MA; VA Keratinocyte Carcinoma Chemoprevention (VAKCC) Trial Group*. Validation and comparison of quality-of-life measures for topical 5-fluorouracil treatment: results from a randomized controlled trial. Clin Exp Dermatol. 2017 Jul;42(5):488-495. doi: 10.1111/ced.13089.</citation>
    <PMID>28621489</PMID>
  </results_reference>
  <results_reference>
    <citation>Korgavkar K, Weinstock MA, Lee KC; VAKCC Trial Group. Evaluation of photoaging scales in an elderly male population. J Eur Acad Dermatol Venereol. 2017 Nov;31(11):e489-e490. doi: 10.1111/jdv.14330. Epub 2017 Jun 20.</citation>
    <PMID>28500658</PMID>
  </results_reference>
  <results_reference>
    <citation>Yoon J, Phibbs CS, Chow A, Weinstock MA; Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial Group. Impact of topical fluorouracil cream on costs of treating keratinocyte carcinoma (nonmelanoma skin cancer) and actinic keratosis. J Am Acad Dermatol. 2018 Mar 2. pii: S0190-9622(18)30344-X. doi: 10.1016/j.jaad.2018.02.058. [Epub ahead of print]</citation>
    <PMID>29505863</PMID>
  </results_reference>
  <results_reference>
    <citation>Leader NF, Means AD, Robinson-Bostom L, Telang GH, Wilkel CS, Weinstock MA; Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial group. Interrater reliability for histopathologic diagnosis of keratinocyte carcinomas. J Am Acad Dermatol. 2018 Jan;78(1):185-187. doi: 10.1016/j.jaad.2017.07.024.</citation>
    <PMID>29241779</PMID>
  </results_reference>
  <results_reference>
    <citation>Korgavkar K, Lee KC, Weinstock MA; Veterans Affairs Keratinocyte Carcinoma Chemoprevention (VAKCC) Trial Group. Effect of Topical Fluorouracil Cream on Photodamage: Secondary Analysis of a Randomized Clinical Trial. JAMA Dermatol. 2017 Nov 1;153(11):1142-1146. doi: 10.1001/jamadermatol.2017.2578.</citation>
    <PMID>28877312</PMID>
  </results_reference>
  <results_reference>
    <citation>Weinstock MA, Thwin SS, Siegel JA, Marcolivio K, Means AD, Leader NF, Shaw FM, Hogan D, Eilers D, Swetter SM, Chen SC, Jacob SE, Warshaw EM, Stricklin GP, Dellavalle RP, Sidhu-Malik N, Konnikov N, Werth VP, Keri JE, Robinson-Bostom L, Ringer RJ, Lew RA, Ferguson R, DiGiovanna JJ, Huang GD; Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial (VAKCC) Group. Chemoprevention of Basal and Squamous Cell Carcinoma With a Single Course of Fluorouracil, 5%, Cream: A Randomized Clinical Trial. JAMA Dermatol. 2018 Feb 1;154(2):167-174. doi: 10.1001/jamadermatol.2017.3631.</citation>
    <PMID>29299592</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2009</study_first_submitted>
  <study_first_submitted_qc>February 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2009</study_first_posted>
  <results_first_submitted>November 7, 2016</results_first_submitted>
  <results_first_submitted_qc>January 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 17, 2017</results_first_posted>
  <disposition_first_submitted>August 11, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>August 11, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 15, 2014</disposition_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NMSC</keyword>
  <keyword>nonmelanoma skin cancer</keyword>
  <keyword>topical 5-FU 5% cream</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Antineoplastic Agents</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Dermatologic Agents</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>carcinoma, basal cell</keyword>
  <keyword>carcinoma, squamous cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
    <mesh_term>Neoplasms, Basal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: 5-fluorouracil</title>
          <description>Group assigned to blinded 5-FU (5-fluorouracil) cream applied to face and ears twice daily for maximum of 56 doses
5-fluorouracil: Apply thin layer of topical 5-FU 5% cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily 5-FU, they will discontinue the treatment and initiate &quot;cool-down&quot; treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping 5-FU, if and only if the participant has not received at least the minimum 2 week (28 dose) course, 5-FU treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the &quot;cool-down&quot; routine will be followed, but 5-FU will be stopped.</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: Placebo, Vehicle Control</title>
          <description>Group assigned to blinded placebo, vehicle control cream applied to face and ears twice daily for maximum of 56 doses
Placebo, vehicle control: Apply thin layer of vehicle control cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily vehicle control cream, they will discontinue the treatment and initiate &quot;cool-down&quot; treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping vehicle control cream, if and only if the participant has not received at least the minimum 2 week (28 dose) course, vehicle control cream treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the &quot;cool-down&quot; routine will be followed, but vehicle control cream will be stopped.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="477"/>
                <participants group_id="P2" count="477"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="468"/>
                <participants group_id="P2" count="464"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: 5-fluorouracil</title>
          <description>Group assigned to blinded 5-FU (5-fluorouracil) cream applied to face and ears twice daily for maximum of 56 doses
5-fluorouracil: Apply thin layer of topical 5-FU 5% cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily 5-FU, they will discontinue the treatment and initiate &quot;cool-down&quot; treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping 5-FU, if and only if the participant has not received at least the minimum 2 week (28 dose) course, 5-FU treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the &quot;cool-down&quot; routine will be followed, but 5-FU will be stopped.</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: Placebo, Vehicle Control</title>
          <description>Group assigned to blinded placebo, vehicle control cream applied to face and ears twice daily for maximum of 56 doses
Placebo, vehicle control: Apply thin layer of vehicle control cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily vehicle control cream, they will discontinue the treatment and initiate &quot;cool-down&quot; treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping vehicle control cream, if and only if the participant has not received at least the minimum 2 week (28 dose) course, vehicle control cream treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the &quot;cool-down&quot; routine will be followed, but vehicle control cream will be stopped.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="468"/>
            <count group_id="B2" value="464"/>
            <count group_id="B3" value="932"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.7" spread="9.2"/>
                    <measurement group_id="B2" value="71.5" spread="9.4"/>
                    <measurement group_id="B3" value="71.1" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="457"/>
                    <measurement group_id="B2" value="459"/>
                    <measurement group_id="B3" value="916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="464"/>
                    <measurement group_id="B2" value="459"/>
                    <measurement group_id="B3" value="923"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="455"/>
                    <measurement group_id="B2" value="457"/>
                    <measurement group_id="B3" value="912"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="468"/>
                    <measurement group_id="B2" value="464"/>
                    <measurement group_id="B3" value="932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Time to Diagnosis of the First Keratinocyte Carcinoma (KC) on the Face or Ears for Which Surgery is Performed</title>
        <description>Diagnosis of the first Primary Basil Cell Carcinoma (BCC) or primary Squamous Cell Carcinoma (SCC) on the face or ears that was removed surgically.</description>
        <time_frame>From randomization to last visit prior to end of study date (6/30/2013), assessed up to four years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: 5-fluorouracil</title>
            <description>Group assigned to blinded 5-fluorouracil (5-FU) cream applied to face and ears twice daily for maximum of 56 doses
5-fluorouracil: Apply thin layer of topical 5-FU 5% cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily 5-FU, they will discontinue the treatment and initiate &quot;cool-down&quot; treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping 5-FU, if and only if the participant has not received at least the minimum 2 week (28 dose) course, 5-FU treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the &quot;cool-down&quot; routine will be followed, but 5-FU will be stopped.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Placebo, Vehicle Control</title>
            <description>Group assigned to blinded placebo, vehicle control cream applied to face and ears twice daily for maximum of 56 doses
Placebo, vehicle control: Apply thin layer of vehicle control cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily vehicle control cream, they will discontinue the treatment and initiate &quot;cool-down&quot; treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping vehicle control cream, if and only if the participant has not received at least the minimum 2 week (28 dose) course, vehicle control cream treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the &quot;cool-down&quot; routine will be followed, but vehicle control cream will be stopped.</description>
          </group>
        </group_list>
        <measure>
          <title>The Time to Diagnosis of the First Keratinocyte Carcinoma (KC) on the Face or Ears for Which Surgery is Performed</title>
          <description>Diagnosis of the first Primary Basil Cell Carcinoma (BCC) or primary Squamous Cell Carcinoma (SCC) on the face or ears that was removed surgically.</description>
          <units>years</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
                <count group_id="O2" value="464"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.37" lower_limit="3.21">Upper 95% confidence interval could not be estimated due to an insufficient number of participants with events</measurement>
                    <measurement group_id="O2" value="3.52" lower_limit="3.08" upper_limit="3.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.93</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hazard Ratio for Surgically Treated KC</title>
        <time_frame>date of randomization to last visit before end of study follow up (6/30/2013), assessed up to four years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: 5-fluorouracil</title>
            <description>Group assigned to blinded 5-FU (5-fluorouracil) cream applied to face and ears twice daily for maximum of 56 doses
5-fluorouracil: Apply thin layer of topical 5-FU 5% cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily 5-FU, they will discontinue the treatment and initiate &quot;cool-down&quot; treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping 5-FU, if and only if the participant has not received at least the minimum 2 week (28 dose) course, 5-FU treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the &quot;cool-down&quot; routine will be followed, but 5-FU will be stopped.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Placebo, Vehicle Control</title>
            <description>Group assigned to blinded placebo, vehicle control cream applied to face and ears twice daily for maximum of 56 doses
Placebo, vehicle control: Apply thin layer of vehicle control cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily vehicle control cream, they will discontinue the treatment and initiate &quot;cool-down&quot; treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping vehicle control cream, if and only if the participant has not received at least the minimum 2 week (28 dose) course, vehicle control cream treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the &quot;cool-down&quot; routine will be followed, but vehicle control cream will be stopped.</description>
          </group>
        </group_list>
        <measure>
          <title>Hazard Ratio for Surgically Treated KC</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
                <count group_id="O2" value="464"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                    <measurement group_id="O2" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.93</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Active monitoring of Adverse Events and Serious Adverse Events began when the participant signed the Consent Form. Adverse Event data collection ended when the participant ended study participation, and Serious Adverse Event data collection continued until 30 days after study participation ended, assessed up to four years.</time_frame>
      <desc>Adverse events collected were those related to the study intervention. Data on adverse events were collected spontaneously through patient reports, actively elicited at each clinic visit through open ended questionings and examination, and gathered at the time of telephone contact during the therapy period. All serious adverse events were collected, including those considered related and unrelated to the study interventions.Subjects were monitored for SAE at each study visit and telephone call.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: 5-fluorouracil</title>
          <description>Group assigned to blinded 5-FU (5-fluorouracil) cream applied to face and ears twice daily for maximum of 56 doses
5-fluorouracil: Apply thin layer of topical 5-FU 5% cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily 5-FU, they will discontinue the treatment and initiate &quot;cool-down&quot; treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping 5-FU, if and only if the participant has not received at least the minimum 2 week (28 dose) course, 5-FU treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the &quot;cool-down&quot; routine will be followed, but 5-FU will be stopped.</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: Placebo</title>
          <description>Group assigned to blinded placebo, vehicle control cream applied to face and ears twice daily for maximum of 56 doses
Placebo, vehicle control: Apply thin layer of vehicle control cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily vehicle control cream, they will discontinue the treatment and initiate &quot;cool-down&quot; treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping vehicle control cream, if and only if the participant has not received at least the minimum 2 week (28 dose) course, vehicle control cream treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the &quot;cool-down&quot; routine will be followed, but vehicle control cream will be stopped.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="190" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Retroperitoneal lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="468"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="468"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="468"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic arteriovenous malformation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Heart disease congenital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Diverticulitis intestinal haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Intestinal mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Oesophageal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pancreatitis necrotising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="468"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adhesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="468"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="468"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="468"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Endocarditis enterococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Incision site cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="468"/>
                <counts group_id="E2" events="26" subjects_affected="21" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="468"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Urinary tract infection pseudomonal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Cardiac procedure complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Device toxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="468"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Post procedural swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Postoperative fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Radiation oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Vascular bypass dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Cardiac monitoring</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Bursa disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Facial asymmetry</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="468"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Benign salivary gland neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Colon cancer stage III</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma stage IV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Lip and/or oral cavity cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="468"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Myeloid leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Osteosarcoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Plasmacytoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="468"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Prostate cancer recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Renal cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Salivary gland cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Salivary gland neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the oral cavity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Basal ganglia stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Basilar artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="468"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Intracranial haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Moyamoya disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="468"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Vascular dementia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder with anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Binge drinking</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Delirium tremens</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Self-injurious ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Substance abuse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Suicidal behaviour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Prostatic haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Scrotal swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="468"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Dyspnoea paroxysmal nocturnal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Vocal cord atrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Hidradenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Respite care</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Social stay hospitalisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Angioplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Carotid endarterectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Chemotherapy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Coronary angioplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Elective procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tube insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Hernia repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Medical device change</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Medical device removal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Oesophagogastric fundoplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Parotidectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Plasmapheresis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Rehabilitation therapy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Skin graft</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Therapeutic procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Vena cava filter insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Wound treatment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Air embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Aortic occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Labile hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="451" subjects_at_risk="468"/>
                <counts group_id="E2" subjects_affected="227" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Iris cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Oral discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Tooth loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Feeling of body temperature change</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="468"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Syringe issue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Temperature intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental exposure to product</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="468"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Traumatic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arteriogram coronary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Emergency care examination</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="468"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Tunnel vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Haemorrhage urinary tract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Sinus disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="468"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Blood blister</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="495" subjects_affected="447" subjects_at_risk="468"/>
                <counts group_id="E2" events="218" subjects_affected="187" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Post inflammatory pigmentation change</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Scab</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Sebaceous hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Seborrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Skin discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Skin haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Skin mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Skin tightness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bladder catheterisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Blepharoplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Oral surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Wound drainage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="468"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="464"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="468"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="464"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Martin Weinstock MD, PhD</name_or_title>
      <organization>Providence VA mendical Center</organization>
      <phone>401-457-3333</phone>
      <email>Martin.Weinstock@va.gov; Martin_Weinstock_MD@brown.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

